Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 64, Issue 6, 2012, Pages 1828-1837

  Watanabe, Junji ^a   Charles Schoeman, Christina ^b   Miao, Yunan ^c   Elashoff, David ^b   Lee, Yuen Yin ^b   Katselis, George ^c,d   Lee, Terry D ^c   Reddy, Srinivasa T ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; FIBRINOGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; SERUM AMYLOID A;

ADULT; ANTIBODY AFFINITY; ARTICLE; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PROTEOMICS; RHEUMATOID ARTHRITIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ACUTE-PHASE PROTEINS; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 84861809556     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34363     Document Type: Article

References (42)

1. Sattar N, McCarey DW, Capell H, McInnes IB,. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
2. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A,. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003; 48: 1833-40.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
4. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE,. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
5. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A,. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002; 29: 906-12.
6. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7.
7. Miller GJ, Miller NE,. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1: 16-9.
8. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al, the Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR,. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62: 707-14.
10. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB,. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256: 2835-8.
11. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
12. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-94.
13. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high- density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-6.
14. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
15. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM,. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001; 103: 2283-8.
16. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice: a novel biomarker of atherosclerosis. J Biol Chem 2007; 282: 23698-707.
17. Mackness MI, Durrington PN, Mackness B,. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004; 4: 211-7.
18. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-8.
19. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-9.
20. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-9.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
23. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
24. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM,. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42: 1308-17.
25. Furlong CE, Richter RJ, Seidel SL, Motulsky AG,. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988; 43: 230-8.
26. Keller A, Nesvizhskii AI, Kolker E, Aebersold R,. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74: 5383-92.
27. Nesvizhskii AI, Keller A, Kolker E, Aebersold R,. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75: 4646-58.
28. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, et al. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 2009; 284: 18292-301.
29. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-69.
30. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al. Anti-inflammatory therapy with tumour necrosis factor α inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868-72.
31. Witztum JL, Steinberg D,. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
32. Witztum JL, Steinberg D,. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
33. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
34. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-42.
35. Hayek T, Oiknine J, Brook JG, Aviram M,. Role of HDL apolipoprotein E in cellular cholesterol efflux: studies in apo E knockout transgenic mice. Biochem Biophys Res Commun 1994; 205: 1072-8.
36. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, et al. The double jeopardy of HDL. Ann Med 2005; 37: 173-8.
37. Heinecke JW,. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2009; 50 Suppl: S167-71.
38. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD,. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 640-4.
39. 2 to this atherogenic profile. Arthritis Rheum 2001; 44: 2761-7.
40. Puppo A, Halliwell B,. Formation of hydroxyl radicals from hydrogen peroxide in the presence of iron. Is haemoglobin a biological Fenton reagent? Biochem J 1988; 249: 185-90.
41. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49: 1344-52.
42. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007; 34: 1459-64.